Facebook Twitter RSS Feed

You are here

Electrophysiology & Arrhythmia

 - heart geometry

Keeping patients with atrial fibrillation on rather than off warfarin therapy during radiofrequency catheter ablation reduced the risk of periprocedural stroke in a randomized trial. The results were published online April 17 in Circulation.

 - heart_drawing

Physicians tend to underestimate both stroke and bleeding risk when deciding whether or not to treat atrial fibrillation (AF) patients with oral anticoagulants. An analysis published online March 29 in Circulation found that in up to 80 percent of cases, physician-assessed risk differed from objective risk scores.

 - EKG, heart

Updated recommendations for the treatment of nonvalvular atrial fibrillation now call for the use of radio frequency ablation as a treatment, a joint American Heart Association, American College of Cardiology and Heart Rhythm Society panel wrote in its 2014 guidelines issued March 28.

 - heart_drawing

The use of a leadless, self-contained pacemaker was found to be safe and effective in a group of patients with an indication for single-chamber pacing who participated in a clinical trial. The study results were published online March 24 in Circulation.

 - doctor consulting patient computer

Citing two cases involving recalled leads in implantable cardiac devices as examples, two California researchers called for more postmarketing surveillance, publicly available data registries and better labeling to help physicians assess devices’ risks and benefits.


More Stories

Warfarin may benefit CKD patients without adding bleeding risk

Compared with non-users, Swedish patients with advanced chronic kidney disease (CKD) and atrial fibrillation who received warfarin therapy were less likely to die, have an MI or stroke at no added risk of bleeding in an observational study published March 5 in JAMA.

FDA approves catheter for AF ablation

The FDA approved a therapeutic catheter that can be used to measure contact force during cardiac ablation.

Temporarily stopping anticoagulation with AF common but risky

Temporarily interrupting anticoagulation therapy in patients with atrial fibrillation (AF) is common and may carry considerable risk for bleeding and strokes, regardless of whether they are treated with rivaroxaban or warfarin, a study published online Feb. 19 in Circulation found.


RAAFT-2 favors ablation over drugs but highlights risks

Radiofrequency ablation appears to have a leg up on standard therapy for treating patients with paroxysmal atrial fibrillation (AF), based on results of the RAAFT-2 trial published in the Feb. 19 issue of JAMA. But both treatments had a high recurrence rate and ablation was far from risk-free.

Dronedarone guidelines may be short on evidence

Clinical practice guidelines involving dronedarone, a drug used to control arrhythmias in patients with atrial fibrillation, may not be based on the best available evidence, a special communication published online Feb. 17 in JAMA Internal Medicine found.

List helps EPs steer clear of inappropriate care

A subcommittee of the Heart Rhythm Society (HRS) published a list of five treatments and procedures electrophysiologists should avoid in patients with arrhythmias. The five “don’ts” are available on the HRS website.

Ablation tech chief retires as part of St. Jude integration

Frank J. Callaghan retired as president of the Cardiovascular and Ablation Technologies Division at St. Jude Medical as the company initiated organizational changes.

Aspirin may be overprescribed in patients with AF

Although aspirin can cause potentially serious adverse effects, it is still overprescribed to prevent strokes in patients with atrial fibrillation (AF), according to a study published online Jan. 28 in The American Journal of Medicine.

Combo AF therapy may not lower risk of coronary events, thromboembolism

Antiplatelet therapy in addition to a vitamin K antagonist in patients with atrial fibrillation (AF) and stable coronary artery disease  may not lower the risk of recurrent coronary events or thromboembolism, according to a study published online Jan. 27 in Circulation.


Judge allows Riata lawsuits to move forward

A federal judge ruled that five product liability claims against St. Jude Medical over its Riata defibrillator leads can move forward.

Repeat cryoablation may offer long-term freedom for some AF patients

About half of patients with paroxysmal atrial fibrillation (AF) who underwent cryoballoon-based pulmonary vein ablation in the STOP AF trial experienced early recurrences of AF. Within that early recurrence subset, those who chose repeat ablation were more likely to be AF-free at one year.

Evidence on efficacy of ICDs at preventing SCD mixed

Using implantable cardioverter-defibrillators (ICDs) to prevent sudden cardiac death (SCD) was more effective than not using ICDs at lowering the risk for mortality and SCD, a meta-analysis published online Jan. 21 in Annals of Internal Medicine found. However, evidence from multiple studies was too weak to suggest a mortality or SCD benefit among different subgroups.


Today’s CIEDs: A hodgepodge of PMA supplements?

Modifications in many of the cardiac implantable electronic devices (CIEDs) currently used in clinical practice were approved through processes that did not require new clinical data, a study published in the Jan. 22-29 issue of JAMA found.

Antibiotics linked to warfarin over-anticoagulation

Antibiotics may increase the risk of excessive anticoagulation among patients with warfarin, according to a study published online Jan. 20 in JAMA Internal Medicine. The absolute risk, however, was low.

Options when proper care & reimbursement don’t align

What options do physicians and hospitals have when reimbursement rules are out of sync with current clinical guidelines and appropriate use criteria? Cardiologists used implantable cardioverter-defibrillators (ICDs) to illustrate this disconnect in the Jan. 7-14 issue of the Journal of the American College of Cardiology.

ICDs do not improve outcomes in some post-PCI STEMI patients

Patients with STEMI revascularized with PCI who had severely impaired left ventricular ejection fraction (LVEF) but no inducible ventricular tachycardia had good outcomes without the need for an implantable cardioverter-defibrillator (ICD), according to a study published Dec. 31 in Circulation.


Patch challenges Holter monitor for detecting arrhythmias

Is the Holter monitor heading toward obsolescence? One study that compared a lightweight patch to Holter monitors for detecting arrhythmias declared the patch the victor and suggested the newer technology will oust this standard approach.

Dabigatran protocol open for comment until Jan. 13

Physicians or others who want to weigh in on a draft protocol to assess safety outcomes in atrial fibrillation patients newly treated with dabigatran or warfarin have until Jan. 13 to submit comments.

Brady bunching: Here is a story …

In what might appear as nominal itself, a study on nominative determinism found that people with the surname Brady may be prone to bradycardia.

Global atrial fibrillation burden on the rise

More than 33 million people worldwide live with atrial fibrillation and the burden of living with the condition grew nearly 19 percent over the past two decades, a study published online Dec. 17 in Circulation found.